AB-729 (sodium)

• UNSPSC Description:

  AB-729 sodium is a siRNA specifically designed to inhibit viral replication and reduces HBV antigens[1][2]. AB-729 conjugates to a trimer of N-acetylgalactosamine (GalNAc) ligand that promotes uptake into hepatocytes via the asialoglycoprotein receptor (ASGR).

• Target Antigen:

  HBV; Small Interfering RNA (siRNA)

• Type:

  Oligonucleotides

• Related Pathways:

  Anti-infection;Epigenetics

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/ab-729-sodium.html

• Solubility:

  10 mM in H2O

• Smiles:

  [AB-729(sodium)]

• Molecular Weight:

  16148.44

• References & Citations:

  [1]Efthymios P Tsounis, et al. Toward a new era of hepatitis B virus therapeutics: The pursuit of a functional cure. World J Gastroenterol. 2021 Jun 7;27(21):2727-2757.|[2]Arbutus Receives Authorization to Proceed with an Investigational New Drug Application (IND) for AB-729, its Proprietary Subcutaneously-Delivered RNAi Agent.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  Phase 2

• CAS Number:

  [2826248-50-2]